Human amniotic mesenchymal stromal cells (hAMSCs) as potential vehicles for drug delivery in cancer therapy: an in vitro study

Stem Cell Research & Therapy
Arianna BonomiOrnella Parolini

Abstract

In the context of drug delivery, mesenchymal stromal cells (MSCs) from bone marrow and adipose tissue have emerged as interesting candidates due to their homing abilities and capacity to carry toxic loads, while at the same time being highly resistant to the toxic effects. Amongst the many sources of MSCs which have been identified, the human term placenta has attracted particular interest due to its unique, tissue-related characteristics, including its high cell yield and virtually absent expression of human leukocyte antigens and co-stimulatory molecules. Under basal, non-stimulatory conditions, placental MSCs also possess basic characteristics common to MSCs from other sources. These include the ability to secrete factors which promote cell growth and tissue repair, as well as immunomodulatory properties. The aim of this study was to investigate MSCs isolated from the amniotic membrane of human term placenta (hAMSCs) as candidates for drug delivery in vitro. We primed hAMSCs from seven different donors with paclitaxel (PTX) and investigated their ability to resist the cytotoxic effects of PTX, to upload the drug, and to release it over time. We then analyzed whether the uptake and release of PTX was sufficient to inhibit pro...Continue Reading

References

Sep 20, 2001·Proceedings of the National Academy of Sciences of the United States of America·A GonçalvesM A Jordan
Jan 31, 2002·Annual Review of Medicine·Michael M Gottesman
Jul 5, 2003·Placenta·K T ShiverickR K Miller
Jul 29, 2004·Reproductive Toxicology·Martina NovotnaFrantisek Staud
Dec 15, 2005·American Journal of Physiology. Endocrinology and Metabolism·Honggang WangQingcheng Mao
Nov 27, 2007·Journal of Tissue Engineering and Regenerative Medicine·Maddalena SonciniOrnella Parolini
Mar 22, 2008·The Journal of Clinical Investigation·Xiao-Bing ZhangHans-Peter Kiem
Oct 1, 2009·British Journal of Pharmacology·Kirsi Vähäkangas, Päivi Myllynen
Nov 10, 2009·Biochemical Pharmacology·Sarah J HemauerMahmoud S Ahmed
Jul 12, 2011·Advanced Drug Delivery Reviews·Khalid Shah
Jan 21, 2012·Journal of Cellular and Molecular Medicine·Marta MagattiOrnella Parolini
Dec 29, 2012·Current Stem Cell Research & Therapy·Antonietta SiliniIngrid Lang
Feb 8, 2013·Angiogenesis·Guido BocciRomano Danesi
Sep 21, 2013·International Journal of Immunopathology and Pharmacology·A BonomiA Pessina
Mar 7, 2014·Biomolecules & Therapeutics·Na-Young LeeYoung-Sook Kang
Mar 19, 2014·Anti-cancer Drugs·Vincent A de WegerJan H M Schellens
Jan 8, 2015·The New England Journal of Medicine·Sara M TolaneyEric P Winer

❮ Previous
Next ❯

Citations

Mar 19, 2016·Journal of Cellular and Molecular Medicine·Paolo BiginiOrnella Parolini
Sep 27, 2016·The Breast : Official Journal of the European Society of Mastology·Kobra VelaeiJafar Soleimani Rad
Apr 25, 2018·Artificial Cells, Nanomedicine, and Biotechnology·Behrouz FarhadihosseinabadiHassan Niknejad
Mar 14, 2019·Journal of Neuropathology and Experimental Neurology·Man LiTing Lei
Apr 14, 2018·Stem Cell Research & Therapy·Hamideh SalehiValerie Orti
Nov 17, 2016·Proceedings of the National Academy of Sciences of the United States of America·Xinyi JiangFan Yang
Apr 14, 2018·Nature Reviews. Clinical Oncology·Kenneth C ValkenburgKenneth J Pienta
Jan 11, 2020·Cell & Bioscience·Bi Foua Claude Alain GohiSheila Namulondo
Jul 9, 2020·Frontiers in Cell and Developmental Biology·Andrea PapaitAntonietta Rosa Silini
Dec 17, 2018·Journal of Controlled Release : Official Journal of the Controlled Release Society·Hong-Hui WuJian-Qing Gao
Jan 23, 2021·International Journal of Molecular Sciences·Quan-Wen LiuHong-Bo Xin
Dec 31, 2020·Genes·Paz de la Torre, Ana I Flores
Mar 20, 2021·International Journal of Pharmaceutics·Yuanqin SuJianqing Gao
May 6, 2021·Journal of Personalized Medicine·Wanda LattanziOrnella Parolini
Jul 28, 2021·Expert Opinion on Drug Delivery·Yukiya TakayamaMakiya Nishikawa
Mar 29, 2019·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Xiwei JiWilliam C Cho
Apr 8, 2020·Molecular Therapy. Methods & Clinical Development·Nadia El-AkabawyGraça Almeida-Porada

❮ Previous
Next ❯

Methods Mentioned

BETA
FACS
FCS

Software Mentioned

CellQuest
FCS Express

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Breast Tumorigenesis

Breast tumorigenesis involves the production or formation of tumor(s) in breast tissue. Discover the latest research on breast tumorigenesis here.

Breast Cancer: Therapeutic Approaches

Several different therapeutic approaches are used to treat breast cancer. These include chemotherapy, hormonal therapy, targeted therapy, and Immunotherapy. Discover the latest research on breast cancer therapeutic approaches here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.